Texas Pharmacy Exceeds Residency Match Placement Goals

91% Residency Match Placement. National Average: 82%. The University of Texas at Austin College of Pharmacy. American Society of Health-System Pharmacists, 2023 Pharmacy Residency Match.
May 4, 2023
The University of Texas at Austin College of Pharmacy placed in the top ten in the entire country in the percentage of match placements with 91%, compared to the national match placement average of 82%.

UT Pharmacy Earns Highest Residency Match Rate in Texas

#1 Residency Match Placement in Texas
April 19, 2022
Pharmacy schools across the country completed their 2022 Phase I and Phase II residency matches for new or upcoming graduates of their Doctor of Pharmacy (Pharm.D.) programs. The University of Texas at Austin College of Pharmacy placed in the top ten of all pharmacy schools in the nation, and number one in Texas.

Williams Talks to KXAN About How Thin Film Freezing Can Help Treat COVID Patients

A man wearing glasses.
July 30, 2021
Division Head and Professor of Molecular Pharmaceutics and Drug Delivery Dr. Bill Williams was on KXAN News to talk about promising new data from TFF Pharmaceuticals and Augmenta Bioworks. The companies plan to develop Dr. Williams' thin film freezing technology to better deliver antibody treatment directly to the lungs of COVID patients.

Williams Wants to Turn COVID-19 Vaccine into Powder to Help with Storage and Distribution

A powder in a vial.
November 25, 2020
Molecular Pharmaceutics and Drug Delivery Professor Robert O. (Bill) Williams III, Ph.D. talks to CBS Austin about the potential for his thin film freezing technology to increase the shelf life of COVID-19 vaccines when they become available.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.

Live Subject Testing Shows Promising Delivery Method for COVID-19 Antiviral Treatment

A microscopic image.
September 23, 2020
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.